Gilead Announces Long-term Safety And Efficacy Data For Seladelpar In Primary Biliary Cholangitis
- Stock Market Stocks to buy Stocks to sell
admin
- 0
- 1 minute read
(RTTNews) – Gilead Sciences, Inc. (GILD) Wednesday announced positive results from two-year interim analysis of the ongoing ASSURE study evaluating the company’s investigational drug seladelpar for the treatment of primary biliary cholangitis (PBC), a rare, chronic inflammatory l
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-506997606-3aeda39d7c734e459725400f855c816d.jpg "Is Shopping at Big-Box Stores Worth It? Factors to Consider")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1169041231-5052d200552d467baab33417938984a3.jpg "10 Low-Risk Income Sources for a Safer Retirement")
:max_bytes(150000):strip_icc():format(jpeg)/business-team-investment-entrepreneur-trading-discussing-and-analysis-graph-stock-market-trading-stock-chart-concept-1089940388-acef8549576a4d918cb157c6c88ec8a1.jpg "Introduction to Phantom Stocks and SARs")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-991180154-aad62bea33e2473a808a24eb81b8e068.jpg "How the Minimum Wage Impacts Unemployment")
